Synthetic, phosphorothioate antisense oligonucleotide designed to inhibit gene expression in human cytomegalovirus (CMV). Consists of 21 nucleotides in a sequence complementary to the specific portion of CMV messenger RNA which encodes regulatory proteins. Prepn: K. P. Anderson, K. G. Draper, WO 9203456; idem et al., US 5442049 (1992, 1995 both to Isis). Large scale synthesis: M. Andrade et al., Bioorg. Med. Chem. Lett. 4, 2017 (1994). Determn in pharmaceutical formulations by capillary gel electrophoresis: G. S. Srivatsa et al., J. Chromatogr. A 680, 469 (1994). Antiviral activity vs human CMV: R. F. Azad et al., Antimicrob. Agents Chemother. 37, 1945 (1993). Mechanism of action study: K. P. Anderson et al., ibid. 40, 2004 (1996). Pharmacokinetics: J. M. Leeds et al., Drug Metab. Dispos. 25, 921 (1997). Retinal toxicity study: M. Flores-Aguilar et al., J. Infect. Dis. 175, 1308 (1997). Review of pharmacology and therapeutic potential: J. Temsamani et al., Expert Opin. Invest. Drugs 6, 1157-1167 (1997). Series of articles on clinical experience for CMV retinitis in AIDS patients: Am. J. Ophthalmol. 133, 467-498 (2002).
Antiviral.
Antiviral; Polynucleotides